来自专业的译者、企业、网页和免费的翻译库。
i kliniske studier med depotformulering af exenatid havde cirka 45 % af patienterne lave antistoftitre mod exenatid ved studiets afslutning.
in clinical studies of prolonged-release exenatide, approximately 45 % of patients had low titre antibodies to exenatide at study endpoint.